Across TCGA pan-cancer cohorts, MIR595 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR595’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where MIR595 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR595 is over-expressed in tumor.
STAD and PRAD are the cancer types where MIR595 tumor–normal differential expression is most reproducible.